Grant: Collaborative Research and Development Grants
University of Ottawa
$100,000.00
Aptamer-assisted isolation and analysis of tumor-derived exosomes in urine and saliva
EF 2018-19
Résumé
The effective diagnosis and prognosis of cancer depends on the ability to quantitatively measure cancer biomarkers from clinical samples at low concentrations. Tumor-derived exosomes (TEX) have emerged as a promising source of cancer biomarkers for both early cancer detection and anti-cancer treatment monitoring, since TEX carry the cancer biomarkers at high concentration. Because exosomes are stable membrane bodies, they protect the proteins and nucleic acids used as biomarkers from degradation in saliva and urine. Also, TEX can be more easily collected and enriched compared to low abundance biomolecules in body fluids.*In this project, the Berezovski research team at the University of Ottawa and a Canadian medical device company, iNano Medical Incorporated, will develop a diagnostic device for analysis of tumor-derived exosomes in saliva and urine. The device will rely on DNA aptamers to capture and concentrate the exosomes containing the protein and nucleic acid cancer biomarkers, and a microelectromechanical system with long-range surface plasmon-polariton detection will enable quantitative reporting of the biomarkers. This microchip-based, rapid, sensitive, and non-invasive diagnostic device would allow routine testing for cancer detection, determination of the severity of the disease, thus providing high quality diagnosis to guide clinical decision and treatments. This innovative clinical diagnostic technology will accelerate iNano's product development, positively impact Canadian healthcare, and improve the quality of cancer management for patients.*
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
520643-2017
Name nom
Berezovski, Maxim
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
100000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
Aptamer-assisted isolation and analysis of tumor-derived exosomes in urine and saliva
Keyword
NSERC
Application summary
The effective diagnosis and prognosis of cancer depends on the ability to quantitatively measure cancer biomarkers from clinical samples at low concentrations. Tumor-derived exosomes (TEX) have emerged as a promising source of cancer biomarkers for both early cancer detection and anti-cancer treatment monitoring, since TEX carry the cancer biomarkers at high concentration. Because exosomes are stable membrane bodies, they protect the proteins and nucleic acids used as biomarkers from degradation in saliva and urine. Also, TEX can be more easily collected and enriched compared to low abundance biomolecules in body fluids.*In this project, the Berezovski research team at the University of Ottawa and a Canadian medical device company, iNano Medical Incorporated, will develop a diagnostic device for analysis of tumor-derived exosomes in saliva and urine. The device will rely on DNA aptamers to capture and concentrate the exosomes containing the protein and nucleic acid cancer biomarkers, and a microelectromechanical system with long-range surface plasmon-polariton detection will enable quantitative reporting of the biomarkers. This microchip-based, rapid, sensitive, and non-invasive diagnostic device would allow routine testing for cancer detection, determination of the severity of the disease, thus providing high quality diagnosis to guide clinical decision and treatments. This innovative clinical diagnostic technology will accelerate iNano's product development, positively impact Canadian healthcare, and improve the quality of cancer management for patients.*